Skip to main content

Remote Job Finders (RJF)

2026 IPO blitz continues with 4 new biotech filings

With more than 25 companies debuting on the public markets, 2026 has recorded the highest number of biotech IPOs since 2021. Now, four companies—including Iambic Therapeutics and ADARx Pharmaceuticals—are looking to grow this total even further.

Boehringer Ingelheim bets up to $1B in AI-centered solid tumor collab with Envisagenics

Envisagenics’ platform makes use of AI to screen and detect cancer-specific RNA alterations, which Boehringer Ingelheim wants to target through various precision treatment modalities, including multi-specific antibodies, antibody-drug conjugates and T cell engagers.

Telix buys ITM for $1.65B in ‘supercritical’ radiopharma M&A

Aside from its manufacturing and distribution footprint, ITM Isotope Technologies Munich will give Telix Pharmaceuticals the late-stage ITM-11, being developed for gastroenteropancreatic neuroendocrine tumors. The asset was rejected by the FDA last month for manufacturing concerns.
Scroll to top